Will A Brexit Transition Period Meet The Needs Of UK Industry?
Executive Summary
As negotiators prepare to discuss a Brexit “transition period,” the UK and European parliaments have again been debating options for addressing the potential impact on the pharmaceutical supply chain.
You may also be interested in...
Agree A Brexit Transition By March Or See Pharma Waste Money On Contingency Plans, Says UK Cttee
UK health secretary Jeremy Hunt has been told by the Commons health committee that the government must agree a Brexit transition period that preserves the “regulatory status quo,” otherwise companies will be forced to start spending money on contingency planning that may prove unnecessary.
Industry Response To Brexit Survey Key For Future Planning, Says EMA
Sponsors of centrally authorized medicines in the EU are being urged to respond to a survey by the European Medicines Agency aimed at gauging industry's preparedness for Brexit. Companies have until Feb. 9 to complete survey, which the EMA says is critical to help with resource planning and ensuring a smooth transition.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.